API
< Back to situations

[ORGANIZATION]

The Lancet Diabetes & Endocrinology

Featured in 10 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

343 clusters · 1318 sources · last updated

Latest: FDA issues warning for GLP-1 drugs over vision loss risks

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt

[ACTIVE] [HEALTH] [CN] [ES] [GB]

Research on obesity index limitations

5 clusters · 41 sources · last updated

Latest: International study proposes new obesity framework beyond BMI

Scientific studies have increasingly questioned the sufficiency of the Body Mass Index (BMI) for accurately predicting chronic disease risks and assessing obesity. An initial study involving the ChinaHEART cohort of over

[QUIET] [HEALTH] [BR]

Brazil plans semaglutide integration into SUS

12 clusters · 172 sources · last updated

Latest: Anvisa regulates weight-loss medications and seizes irregular supplements

The Brazilian Ministry of Health is progressing with plans to incorporate semaglutide-based weight-loss medications into the Unified Health System (SUS). On September 24, 2026, the Ministry submitted a formal request to

[QUIET] [HEALTH] [US] [DE] [KR]

Research into diabetic kidney disease treatments

6 clusters · 15 sources · last updated

Latest: ASN Kidney Week 2026 highlights new therapies and digital tools for CKD

Scientific research into diabetic kidney disease (DKD) is focusing on novel therapeutic targets, improved monitoring markers, and optimized medication timing. Studies in the ‘Chinese Journal of Natural Medicines’ suggest

Also covered in